Gydush, Gregory
Nguyen, Erica
Bae, Jin H. http://orcid.org/0000-0002-4059-5198
Blewett, Timothy
Rhoades, Justin
Reed, Sarah C.
Shea, Douglas
Xiong, Kan
Liu, Ruolin http://orcid.org/0000-0001-9059-6335
Yu, Fangyan
Leong, Ka Wai
Choudhury, Atish D. http://orcid.org/0000-0001-9344-6631
Stover, Daniel G.
Tolaney, Sara M. http://orcid.org/0000-0002-5940-8671
Krop, Ian E.
Christopher Love, J. http://orcid.org/0000-0003-0921-3144
Parsons, Heather A. http://orcid.org/0000-0001-8178-6612
Mike Makrigiorgos, G. http://orcid.org/0000-0001-7598-2406
Golub, Todd R. http://orcid.org/0000-0003-0113-2403
Adalsteinsson, Viktor A. http://orcid.org/0000-0003-4555-2485
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R33 CA217652, R01 CA221874, R01 CA221874, R33 CA217652)
Gerstner Family Foundation
Article History
Received: 1 May 2020
Accepted: 28 January 2022
First Online: 17 March 2022
Competing interests
: A.D.C. has advisory-board roles with Clovis, Dendreon and Bayer, and has received research funding from Bayer. S.M.T. has received research funding to the institution from AstraZeneca, Eli Lilly, Merck, Novartis, Nektar, Pfizer, Genentech, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Cyclacel, Sanofi, Odonate and Seattle Genetics, and has received honorariums for consulting and advisory-board participation from AstraZeneca, Eli Lilly, Merck, Novartis, Nektar, Pfizer, Genentech, Immunomedics, Bristol-Myers Squibb, Eisai, Nanostring, Sanofi, Odonate, Seattle Genetics, Puma, Anthenex, OncoPep, Abbvie, G1 Therapeutics, Silverback Therapeutics and Celldex. I.E.K. has received research funding to the institute from Genentech, Pfizer and Daichii-Sankyo, and has received honorariums for consulting and advisory-board participation from Genentech, Daichii-Sankyo, Macrogenics, Context Therapeutics, Taiho Oncology, Merck, Novartis and Bristol-Myers Squibb. H.A.P. has a paid consultant role for Foundation Medicine. T.R.G. is a paid advisor to GlaxoSmithKline, and is a co-founder and equity holder of Sherlock Biosciences and FORMA Therapeutics. V.A.A. has a patent application filed with the Broad Institute, and is a member of the scientific advisory boards of Bertis and AGCT, which were not involved in this study. The other authors report no competing interests.